Acrivon Therapeutics Inc (ACRV)

$1.78 0.00 (N/A)
Market Cap 76.19M
Revenue (ttm) 0.00
Net Income (ttm) -77.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 270,800
Avg Vol 577,434
Day's Range N/A - N/A
Shares Out 42.80M
Stochastic %K 95%
Beta 1.90
Analysts Strong Sell
Price Target $11.50

Company Profile

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 207 8979
Website: acrivon.com
Address:
480 Arsenal Way, Suite 100, Watertown, United States
open_outcry
open_outcry Jul. 1 at 2:29 AM
$ACRV what's on tap here catalyst-wise for H2 2026?
1 · Reply
Bullbarbise
Bullbarbise Jun. 30 at 2:41 PM
$ACRV No volumes, no party... Waiting mode
0 · Reply
Dani_G_German
Dani_G_German Jun. 30 at 2:18 AM
$ACRV
0 · Reply
Bullbarbise
Bullbarbise Jun. 29 at 3:41 PM
$ACRV Looking good and very strong.
0 · Reply
PreGigs
PreGigs Jun. 29 at 1:51 PM
$ACRV hey not to bad!
0 · Reply
nmarrone2207
nmarrone2207 Jun. 26 at 8:08 PM
$ACRV looking strong!!
1 · Reply
Dani_G_German
Dani_G_German Jun. 23 at 4:40 PM
$ACRV Going back above 2 soon
1 · Reply
PreGigs
PreGigs Jun. 23 at 4:00 PM
$ACRV just keep loading the boat.
0 · Reply
MrTicker
MrTicker Jun. 22 at 8:33 PM
$ACRV Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: Shah Rajeev M. 10K WIZARD 3:33 PM ET 6/22/2026 http://archive.fast-edgar.com/20260622/A62UF22CZ222UTZ2222G2ZEZUOIRZ8Y24282 Filed on: June 22, 2026
0 · Reply
RotterdamTrade
RotterdamTrade Jun. 22 at 6:07 PM
$ACRV Bought some pieces.
0 · Reply
Latest News on ACRV
Acrivon Therapeutics assumed with an Outperform at Oppenheimer

2026-06-15T11:43:03.000Z - 16 days ago

Acrivon Therapeutics assumed with an Outperform at Oppenheimer

Acrivon Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 26, 2026, 9:00 AM EDT - 5 weeks ago

Acrivon Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Acrivon Therapeutics Proxy statement: Proxy filing

May 22, 2026, 8:00 AM EDT - 5 weeks ago

Acrivon Therapeutics Proxy statement: Proxy filing

Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit

May 21, 2026, 7:30 AM EDT - 5 weeks ago

Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026, 4:00 PM EDT - 6 weeks ago

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)

2026-05-13T21:27:56.000Z - 6 weeks ago

Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

May 13, 2026, 4:10 PM EDT - 6 weeks ago

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

Acrivon Therapeutics Earnings release: Q1 2026

May 13, 2026, 4:00 PM EDT - 6 weeks ago

Acrivon Therapeutics Earnings release: Q1 2026

Acrivon Therapeutics Quarterly report: Q1 2026

May 13, 2026, 4:00 PM EDT - 6 weeks ago

Acrivon Therapeutics Quarterly report: Q1 2026

Acrivon Therapeutics Slides: Corporate presentation

May 13, 2026, 4:00 PM EDT - 6 weeks ago

Acrivon Therapeutics Slides: Corporate presentation

Acrivon Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Acrivon Therapeutics Proxy statement: Proxy filing

Acrivon Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Acrivon Therapeutics Proxy statement: Proxy filing

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

Apr 17, 2026, 4:00 PM EDT - 2 months ago

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c)

2026-03-19T11:25:53.000Z - 3 months ago

Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c)

Acrivon Therapeutics sees cash runway into 2Q27

2026-03-19T11:25:40.000Z - 3 months ago

Acrivon Therapeutics sees cash runway into 2Q27

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 19, 2026, 7:21 AM EDT - 3 months ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Acrivon Therapeutics Earnings release: Q4 2025

Mar 19, 2026, 7:00 AM EDT - 3 months ago

Acrivon Therapeutics Earnings release: Q4 2025

Acrivon Therapeutics Annual report: Q4 2025

Mar 19, 2026, 7:00 AM EDT - 3 months ago

Acrivon Therapeutics Annual report: Q4 2025

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

Mar 17, 2026, 5:54 PM EDT - 3 months ago

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

Acrivon Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:50 PM EST - 4 months ago

Acrivon Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Acrivon Therapeutics Slides: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:50 PM EST - 4 months ago

Acrivon Therapeutics Slides: TD Cowen 46th Annual Health Care Conference

Acrivon Therapeutics Transcript: European Society of Gynecological Oncology (ESGO) Congress 2026

Feb 27, 2026, 8:00 AM EST - 4 months ago

Acrivon Therapeutics Transcript: European Society of Gynecological Oncology (ESGO) Congress 2026

Acrivon Therapeutics Slides: FY 2026

Feb 27, 2026, 8:00 AM EST - 4 months ago

Acrivon Therapeutics Slides: FY 2026

Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 4 months ago

Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress

Feb 23, 2026, 8:00 AM EST - 4 months ago

Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress

Acrivon Therapeutics announces completion, certification of CLIA certified lab

2026-02-18T13:11:04.000Z - 4 months ago

Acrivon Therapeutics announces completion, certification of CLIA certified lab

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory

Feb 18, 2026, 8:00 AM EST - 4 months ago

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress

Jan 23, 2026, 8:11 AM EST - 5 months ago

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress

Acrivon Therapeutics price target raised to $8 from $6 at Piper Sandler

2026-01-09T11:46:33.000Z - 6 months ago

Acrivon Therapeutics price target raised to $8 from $6 at Piper Sandler

Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results

2026-01-08T14:04:25.000Z - 6 months ago

Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results

Acrivon Therapeutics Transcript: Study Update

Jan 8, 2026, 8:30 AM EST - 6 months ago

Acrivon Therapeutics Transcript: Study Update

Acrivon Therapeutics Press release: Study Update

Jan 8, 2026, 8:30 AM EST - 6 months ago

Acrivon Therapeutics Press release: Study Update

Acrivon Therapeutics Slides: Study Update

Jan 8, 2026, 8:30 AM EST - 6 months ago

Acrivon Therapeutics Slides: Study Update

Acrivon Therapeutics announces progress across pipeline

2026-01-08T12:35:54.000Z - 6 months ago

Acrivon Therapeutics announces progress across pipeline

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

Jan 8, 2026, 7:30 AM EST - 6 months ago

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies

2026-01-06T12:41:29.000Z - 6 months ago

Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Jan 6, 2026, 7:30 AM EST - 6 months ago

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Dec 17, 2025, 9:34 AM EST - 7 months ago

UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Acrivon to provide ACR-368, ACR-2316 clinical data in January

2025-12-17T12:36:13.000Z - 7 months ago

Acrivon to provide ACR-368, ACR-2316 clinical data in January

Acrivon Therapeutics reports Q3 EPS (47c), consensus (58c)

2025-11-13T21:50:27.000Z - 8 months ago

Acrivon Therapeutics reports Q3 EPS (47c), consensus (58c)

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 13, 2025, 4:10 PM EST - 8 months ago

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Acrivon Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

Acrivon Therapeutics Earnings release: Q3 2025

Acrivon Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

Acrivon Therapeutics Quarterly report: Q3 2025

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

Oct 22, 2025, 4:15 PM EDT - 8 months ago

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

Acrivon Therapeutics price target lowered to $8 from $9 at Oppenheimer

2025-08-14T10:30:20.000Z - 11 months ago

Acrivon Therapeutics price target lowered to $8 from $9 at Oppenheimer

Acrivon Therapeutics reports Q2 EPS (55c), consensus (58c)

2025-08-13T20:45:13.000Z - 11 months ago

Acrivon Therapeutics reports Q2 EPS (55c), consensus (58c)

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 13, 2025, 4:15 PM EDT - 11 months ago

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Acrivon Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Acrivon Therapeutics Quarterly report: Q2 2025

Acrivon Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Acrivon Therapeutics Earnings release: Q2 2025

Acrivon Therapeutics Slides: Corporate Presentation

Jun 13, 2025, 10:00 AM EDT - 1 year ago

Acrivon Therapeutics Slides: Corporate Presentation

Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch

2025-05-16T16:30:10.000Z - 1 year ago

Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch

Acrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer

2025-05-15T02:20:21.000Z - 1 year ago

Acrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 14, 2025, 4:10 PM EDT - 1 year ago

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Acrivon Therapeutics Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Acrivon Therapeutics Quarterly report: Q1 2025

Acrivon Therapeutics Earnings release: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Acrivon Therapeutics Earnings release: Q1 2025

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Acrivon Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Proxy statement: Proxy Filing

Acrivon Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Proxy statement: Proxy Filing

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Apr 7, 2025, 4:05 PM EDT - 1 year ago

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 5:44 PM EDT - 1 year ago

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Acrivon Therapeutics Earnings release: Q4 2024

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Acrivon Therapeutics Earnings release: Q4 2024

Acrivon Therapeutics Annual report: Q4 2024

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Acrivon Therapeutics Annual report: Q4 2024

Acrivon Therapeutics Transcript: Status Update

Mar 25, 2025, 4:00 PM EDT - 1 year ago

Acrivon Therapeutics Transcript: Status Update

Acrivon Therapeutics Slides: Status Update

Mar 25, 2025, 4:00 PM EDT - 1 year ago

Acrivon Therapeutics Slides: Status Update

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Acrivon Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Acrivon Therapeutics Quarterly report: Q3 2024

Acrivon Therapeutics Earnings release: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Acrivon Therapeutics Earnings release: Q3 2024

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Acrivon Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 8:35 AM EDT - 1 year ago

Acrivon Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Acrivon Therapeutics Transcript: Study Update

Sep 14, 2024, 9:00 AM EDT - 1 year ago

Acrivon Therapeutics Transcript: Study Update

Acrivon Therapeutics Press release: Study Update

Sep 14, 2024, 9:00 AM EDT - 1 year ago

Acrivon Therapeutics Press release: Study Update

Acrivon Therapeutics Slides: Study Update

Sep 14, 2024, 9:00 AM EDT - 1 year ago

Acrivon Therapeutics Slides: Study Update

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Sep 14, 2024, 3:10 AM EDT - 1 year ago

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Acrivon Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Acrivon Therapeutics Quarterly report: Q2 2024

Acrivon Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Acrivon Therapeutics Earnings release: Q2 2024

Acrivon Therapeutics Slides: Corporate Presentation

Jun 4, 2024, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Slides: Corporate Presentation

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 14, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Acrivon Therapeutics Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Quarterly report: Q1 2024

Acrivon Therapeutics Earnings release: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Earnings release: Q1 2024

Acrivon Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Proxy statement: Proxy Filing

Acrivon Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Proxy statement: Proxy Filing

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Apr 24, 2024, 7:16 PM EDT - 2 years ago

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Acrivon Therapeutics Transcript: R&D Update

Apr 24, 2024, 4:15 PM EDT - 2 years ago

Acrivon Therapeutics Transcript: R&D Update

Acrivon Therapeutics Slides: R&D Update

Apr 24, 2024, 4:15 PM EDT - 2 years ago

Acrivon Therapeutics Slides: R&D Update

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Apr 24, 2024, 4:01 PM EDT - 2 years ago

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Acrivon Therapeutics Registration statement: Registration Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Registration statement: Registration Filing

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Apr 16, 2024, 8:01 PM EDT - 2 years ago

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Apr 9, 2024, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Acrivon Therapeutics Annual report: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Annual report: Q4 2023

Acrivon Therapeutics Earnings release: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Earnings release: Q4 2023

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Mar 5, 2024, 4:30 PM EST - 2 years ago

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2024, 4:00 PM EST - 2 years ago

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics Registration statement: Registration Filing

Dec 1, 2023, 7:00 AM EST - 2 years ago

Acrivon Therapeutics Registration statement: Registration Filing

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Nov 21, 2023, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 9, 2023, 8:01 AM EST - 2 years ago

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Acrivon Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Acrivon Therapeutics Quarterly report: Q3 2023

Acrivon Therapeutics Earnings release: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Acrivon Therapeutics Earnings release: Q3 2023

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Sep 19, 2023, 4:32 PM EDT - 3 years ago

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Sep 5, 2023, 4:05 PM EDT - 3 years ago

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Aug 30, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Acrivon Therapeutics Quarterly report: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Quarterly report: Q2 2023

Acrivon Therapeutics Earnings release: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Earnings release: Q2 2023

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Jun 22, 2023, 4:00 PM EDT - 3 years ago

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

Acrivon Therapeutics Proxy statement: Proxy Filing

May 30, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Proxy statement: Proxy Filing

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 9, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Acrivon Therapeutics Quarterly report: Q1 2023

May 9, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Quarterly report: Q1 2023

Acrivon Therapeutics Earnings release: Q1 2023

May 9, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Earnings release: Q1 2023

Acrivon Therapeutics Proxy statement: Proxy Filing

May 1, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Proxy statement: Proxy Filing

Acrivon Therapeutics Proxy statement: Proxy Filing

May 1, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Proxy statement: Proxy Filing

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Mar 28, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Acrivon Therapeutics Annual report: Q4 2022

Mar 28, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Annual report: Q4 2022

Acrivon Therapeutics Earnings release: Q4 2022

Mar 28, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Earnings release: Q4 2022

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 6, 2023, 8:00 AM EST - 3 years ago

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Acrivon Therapeutics Announces Pricing of Initial Public Offering

Nov 14, 2022, 10:16 PM EST - 3 years ago

Acrivon Therapeutics Announces Pricing of Initial Public Offering

open_outcry
open_outcry Jul. 1 at 2:29 AM
$ACRV what's on tap here catalyst-wise for H2 2026?
1 · Reply
Bullbarbise
Bullbarbise Jun. 30 at 2:41 PM
$ACRV No volumes, no party... Waiting mode
0 · Reply
Dani_G_German
Dani_G_German Jun. 30 at 2:18 AM
$ACRV
0 · Reply
Bullbarbise
Bullbarbise Jun. 29 at 3:41 PM
$ACRV Looking good and very strong.
0 · Reply
PreGigs
PreGigs Jun. 29 at 1:51 PM
$ACRV hey not to bad!
0 · Reply
nmarrone2207
nmarrone2207 Jun. 26 at 8:08 PM
$ACRV looking strong!!
1 · Reply
Dani_G_German
Dani_G_German Jun. 23 at 4:40 PM
$ACRV Going back above 2 soon
1 · Reply
PreGigs
PreGigs Jun. 23 at 4:00 PM
$ACRV just keep loading the boat.
0 · Reply
MrTicker
MrTicker Jun. 22 at 8:33 PM
$ACRV Form 4 Acrivon Therapeutics, For: Jun 17 Filed by: Shah Rajeev M. 10K WIZARD 3:33 PM ET 6/22/2026 http://archive.fast-edgar.com/20260622/A62UF22CZ222UTZ2222G2ZEZUOIRZ8Y24282 Filed on: June 22, 2026
0 · Reply
RotterdamTrade
RotterdamTrade Jun. 22 at 6:07 PM
$ACRV Bought some pieces.
0 · Reply
nmarrone2207
nmarrone2207 Jun. 18 at 8:57 PM
$ACRV get ready for boom boom time! Check volume from last 5 mins and into close. 500k came in when the day only had 200. LFG!
0 · Reply
Rolo2024
Rolo2024 Jun. 17 at 9:49 PM
$ACRV Upcoming milestones that should keep bumping up our stock price.
0 · Reply
focafoca99
focafoca99 Jun. 17 at 9:46 PM
$ACRV declares its shareholders approved a new 2022 equity incentive plan, elected two directors and ratified PwC as its auditor.
0 · Reply
nmarrone2207
nmarrone2207 Jun. 16 at 6:46 PM
$ACRV tape change?
1 · Reply
Rolo2024
Rolo2024 Jun. 15 at 9:40 PM
$ACRV Cash runway for 22 months. This is way more than 75% pharma stocks and major readout this year. Pony up!
0 · Reply
Trinity031983
Trinity031983 Jun. 15 at 6:20 PM
$ACRV
0 · Reply
notreload_ai
notreload_ai Jun. 15 at 2:16 PM
Oppenheimer initiates coverage on $ACRV with an Outperform rating and an $8 price target, implying ~440% upside. It highlights strong interim Phase 2b data in serous endometrial cancer. https://notreload.xyz/xy/oppenheimer-sees-440-upside-in-acrivon-therapeutics-as-key-acr-368-data-approaches/
0 · Reply
Dcvfin
Dcvfin Jun. 14 at 1:16 PM
$ACRV these guys are paying $1,000,000 for rent yearly in thier US facility. And paying their CEO over $1,000,000 per year I dont like biotechs that burn investors money so easily No thanks, find some suckers to fund you
2 · Reply
nmarrone2207
nmarrone2207 Jun. 12 at 7:14 PM
$ACRV daily macd cross coming next week... have a feeling going to be paired with some sort of news.
0 · Reply
Dani_G_German
Dani_G_German Jun. 12 at 5:55 PM
$ACRV could get back to 1.87 easily
0 · Reply
Rolo2024
Rolo2024 Jun. 12 at 4:36 PM
$ACRV Building momemtum! Key readout coming later this year and cash on hand for over 15 months! Whats not to like?!
0 · Reply
blackpoint01
blackpoint01 Jun. 11 at 9:57 PM
$ACRV we soon going to be at $10, if the company is doing good there’s no way the stock stay down for ever.!
0 · Reply